Abstract: An oral dissolving film containing nano- or micro-encapsulated bioactive material and methods of forming the film. The film may be prepared by dispensing a mixture of a film-forming agent, a crosslinking agent, a solution of nano- or micro-encapsulated bioactive material, and a photoinitiator into a plurality of wells in a tray using a 3D printer. The dispensed material is exposed to radiation in order to crosslink the material and form a film.

Abstract: There are provided a pearl culture material containing at least one selected from the group consisting of a pearl nucleus and a mantle, and the at least one selected from the group consisting of a pearl nucleus and a mantle contains a protein having 10 EU/g or less of an endotoxin amount, a nucleus insertion method, and a pearl culture material composition.

Abstract: The present invention relates to methods for treating patients having cancer or a premalignant or neoplastic condition. It is based, at least in part, on the discovery that a genome editing technique that specifically targets a fusion gene can induce cell death in a cancer cell other than a prostate cancer cell, e.g., a hepatocellular cancer cell, having the fusion gene. The present invention provides methods for treating cancer patients that include performing a genome editing technique targeting a fusion gene present within one or more cells of a subject to produce an anti-cancer effect.

Abstract: A cleaning composition may include at least one linear alkylbenzene sulfonate, at least one fatty alcohol ether sulfate, an active protein of at least one amylase having at least 90% sequence identity with the amino acid sequence recited in SEQ ID NO:1 or SEQ ID NO:2, an active protein of at least one protease having at least 90% sequence identity with the amino acid sequence recited in SEQ ID NO:3 or SEQ ID NO:4, at least one betaine, optional additional substances and/or additives, and water.

Abstract: The disclosure pertains to the field of molecular means capable of binding to, and preferably of chelating, cGMP, appropriate for use in vitro or in vivo and preferably capable of targeting specific cellular compartments. The polypeptides of the disclosure comprise a chimeric construction derived from the N terminus part of PKG-I? and PKG-I?, and the two cGMP binding sites of the wild type PKG.

Abstract: The present disclosure provides amphiphilic fluorinated surfactant molecules for lowering the surface tension of aqueous, hydrocarbon, or solid phases in the presence of a fluorophilic continuous phase and for selectively interacting with biological and/or chemical molecules.

Abstract: Methods for making hemoglobin based blood substitute preparations and hemoglobin based blood substitute preparations. The methods involve preparing a low purity erythrocyte protein fraction comprising hemoglobin protein and endogenous non-hemoglobin protein complement, and chemically modifying the proteins in the protein fraction to form a cross-linked hemoglobin containing blood substitute preparation. The low purity erythrocyte protein preparation can contain from at least about 0.2% (mole/mole) up to about 20% (mole/mole) endogenous non-hemoglobin protein complement. At least about 90% (mole/mole) of the hemoglobin proteins can be cross-linked, so that the average molecular mass of cross-linked proteins comprising hemoglobin protein molecules in the preparation is at least about 300 kDa. The preparations can be used to prepare finished blood substitute formulations for in-vivo and ex-vivo use.

Abstract: The present disclosure provides methods and compositions for directed to synthetic block copolymer proteins, expression constructs for their secretion, recombinant microorganisms for their production, and synthetic fibers (including advantageously, microfibers) comprising these proteins that recapitulate many properties of natural silk. The recombinant microorganisms can be used for the commercial production of silk-like fibers.

Abstract: The present invention relates to xylanase variants, polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; compositions comprising the xylanase variants and methods of using the variants.

Abstract: Compositions, methods and kits are provided for identifying the presence and location of a target in chromosomal DNA. A nicking endonuclease fused to a binding domain that binds to a constant region of an antibody (NEFP) is provided that may be used for binding to a target directly or via an antibody that binds to the target. The target may be a protein or structural feature of the DNA and its presence and location may correspond to a phenotype and/or pathology in a biopsy or other cell sample for diagnostic purposes. The background is reduced by the addition of a glycoaminoglycan (GAG) that reversibly inhibits binding of the NEFP to DNA. Nick translation in the presence of a strand displacing polymerase enables the incorporation of tagged nucleotides that (i) blocks re-nicking; (ii) facilitates immobilization of DNA fragments around the target for sequencing; and/or (iii) enables dye labelling of the chromosomal DNA within the cell nuclei for analysis by microscopy.

Abstract: A process for producing rotundone from ?-guaiene, in particular by oxidation of the C(3) position, wherein the ?-guaiene is produced from a precursor by a sesquiterpene synthase. The sesquiterpene synthase is produced in a microorganism.

Abstract: The present invention discloses a new efficient process for the preparation of the KDR-targeting peptide-phospholipid conjugate of formula (I), which can be useful in therapeutic and diagnostic compositions and particularly in the preparation of ultrasound contrast agents.

Abstract: The present disclosure provides proteins, nucleic acids, vectors, and host molecules useful for the production of compounds of interest, and methods for their use.

Abstract: An object of the present invention is to provide a soluble RNA-binding protein having high binding ability. The present invention provides an RNA-binding protein having an amino acid sequence represented by R1?-R1X—R2X—(R5X or R6Y)L-(R5X—R6Y)M-(R5X or R6Y)N—R7X—R8X—R8? wherein each symbol means an amino acid sequence recited in the specification.

Abstract: Reaction compositions are disclosed herein comprising at least water, beta-glucose -1-phosphate (beta-G1P), an acceptor molecule, and an alpha-1,3-glucan phosphorylase enzyme. These reactions can synthesize oligosaccharides and polysaccharides with alpha-1,3 glycosidic linkages. Further disclosed are alpha-1,3-glucan phosphorylase enzymes and methods of use thereof.

Abstract: Disclosed are mutated phosphotriesterase enzymes with improved stability and activity, as well as their use in particular for degrading organophosphorus compounds.

Abstract: Described herein are cholix-IL-10 fusion proteins, and methods of use thereof, which can be characterized by a distinct response in an individual when administered. This distinct response can comprise changes in levels of one or more markers in the individual and/or co-localization of IL-10 in the Lamina propria of the individual. Further described herein, in some embodiments, are oral formulations of the cholix-IL-10 fusion proteins. Described herein are methods for the purification of an IL-10 delivery construct, including methods for refolding and enrichment, which can result in maintenance of a high percentage of the IL-10 delivery constructs in the biologically active dimer form. Described herein are oral formulations configured for site-specific release of a therapeutic protein in the small intestines or colon. In some cases, the therapeutic protein is in the form of a dimer, such as an IL-10 delivery construct capable of crossing the gut epithelium.

Abstract: The present invention relates to polypeptide variants and methods for obtaining variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.

Abstract: Sialic acid recognizing-affinity reagents engineered from the neuraminidase NanB have lectin-like properties and defined specificities for sialic acid.

Abstract: The invention relates to a polypeptide comprising or consisting of the polypeptide of SEQ ID NO: 1 wherein the residue X at position 89 of SEQ ID NO: 1 is not a cysteine, or a functionally equivalent variant of said polypeptide wherein the residue X at position 89 of SEQ ID NO: 1 is not a cysteine and their use in medicine, particularly in the prevention and/or treatment of cancer.